Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr-Jun;28(2):173-181.

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors

Hariklia Kranidioti  1 , Spilios Manolakopoulos  2 , Salim I Khakoo  1
Affiliations
Review

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors

Hariklia Kranidioti et al. Ann Gastroenterol. 2015 Apr-Jun.

Abstract

The introduction of nucleot(s)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome of patients with chronic hepatitis B. NAs appear to be safe and induce potent suppression of viral replication. However, they are associated with a low rate of HBsAg seroclearance, the gold standard of successful treatment, and also with a relatively high rate of virological relapse after discontinuation. As a result, long-term treatment is needed. The optimal duration of NA treatment currently remains unclear, nevertheless in some patients NA treatment can be stopped with a relatively low probability of relapse. Whether NAs are able to induce a sustained off-treatment response is an important area for research. This article reviews the relapse rate after cessation of treatment with NAs in chronic hepatitis B patients with the goal of identifying possible predictive factors of relapse.

Keywords: Chronic hepatitis B; nucleot(s)ides analogues; stopping therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: HK is a recipient of a Fellowship from the Hellenic Association for the Study of the Liver

References

    1. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283. - PMC - PubMed
    1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185. - PubMed
    1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. - PubMed
    1. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 2004;24(Suppl 1):17–21. - PubMed
    1. Ruan P, Xu SY, Zhou BP, et al. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study. J Int Med Res. 2013;41:1732–1739. - PubMed

LinkOut - more resources